Drugs In The Making
  • Shruti's Blog
  • About Shruti Bhat
  • QUALITY BLOG
  • Industry News
  • Free Ebook
  • Research Updates
    • Drug Research
    • Clinical Research
  • Contact

Drug Research Updates

FDA warns against using four asthma drugs as stand-alones or for extended periods.

2/24/2010

0 Comments

 
Picture
Dr.Shruti Bhat, an Expert in Pharmaceutical industry, brings to you some highlights from current pharma and clinical research news, views and data.

FDA warns against using four asthma drugs as stand-alones or for extended periods.

The Los Angeles Times  reported  that the FDA "on Thursday called for putting new limits on powerful and long-lasting bronchial drugs" containing both long-acting beta agonists, commonly called LABAs, and inhaled corticosteroids, in "a move designed to lower the risk of complications leading to hospitalization or even death." The agency "said patients should use products containing only the corticosteroids or other asthma-relieving medication whenever possible." Meanwhile, "patients who cannot control asthma symptoms any other way should use LABAs for the shortest possible time, but the drugs should never be used alone in treating asthma in adults or children, the agency said."

FDA Clears Drug To Treat Respiratory Symptoms Of Cystic Fibrosis.

The Food and Drug Administration has approved for marketing Gilead Sciences, Inc.'s "drug Cayston [aztreonam for inhalation solution] as a treatment for respiratory symptoms of cystic fibrosis, the company said Tuesday." The company "said it plans to make the drug available by the end of next week."  The San Francisco Business Times  reported that "Cayston, administered three times a day over a 28-day period, treats the bacteria Pseudomonas aeruginosa, which causes mucus to build up in the lungs and digestive tract of cystic fibrosis patients," and which is also "the single greatest cause of death for CF patients."

FDA Panel Recommends Approval Of Xifaxan To Treat Hepatic Encephalopathy.
A  Food and Drug Administration panel "recommended Salix Pharmaceutical's drug Xifaxan [rifaximin] be approved to treat" hepatic encephalopathy, which is "brain damage caused by liver failure." In a 14-to-4 vote, the panel found that "the drug's benefits warrant its approval. In a separate vote, the panel also voted 14-4 in favor of the drug's safety." The agency will consider its panel's vote when it makes a final decision anticipated by Mar. 24. Reuters also noted that the FDA has already approved Xifaxan to treat travel-related diarrhea.

Three Major US Drugmakers Create Asian Cancer Research Group.
Three major US drugmakers, Eli Lilly and Co., Merck & Co., and Pfizer Inc., said Tuesday they have formed a not-for-profit company in Asia to focus on cancer research and treatments." The Asian Cancer Research Group will "focus on the most commonly diagnosed cancers in Asia, including lung and gastric cancers." The companies aim to "create an extensive database that will be made available to researchers."

Disclaimer- The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances. 

Also at http://www.pharm-education.com/2010/02/three-major-us-drugmakers-create-asian.html

http://www.drshrutibhat.com
Expert at leading Pharmaceutical R&D.
Translates innovative concepts to PROFITS.
Do you have questions for the author? 

0 Comments

Your comment will be posted after it is approved.


Leave a Reply.

    shruti bhat, pharmaceutical manufacturing and continuous improvement expert
    Dr. Shruti Bhat

    Pharmaceutical Manufacturing, Continuous Improvement and Business Transformation Consultant


    Picture

    how to choose business process improvement methodology
    18 business process improvement methodologies, shruti bhat

    Categories

    All
    Drug Research Updates


      Contact

    SEND
Disclaimer:

The website, blog information, audios, videos, white papers and all other associated published content on this website is the sole property of Innoworks, Canada and is under Copy Right protection. Not to be copied, distributed or used without prior authorization of the owner. The blog provides information for general knowledge sharing for community benefit and is for academic purpose only. Please give courtesy credits to respective authors in case information published here is used as a reference.
 
Additionally, information published on the blog, resource library etc. should not be considered or construed as legal and/or medical advice.  For diagnosis of an ailment, it is recommended that one seeks help of a registered medical practitioner, while medicines should be received from a registered pharmacist only. Seek advise of registered legal expert for any information pertaining law(s).

 The authors and website owner have used their best efforts in preparing this site. The information contained herein has been stated accurately to the best ability of the authors. The information contained herein is strictly for educational purposes. The author and website owner make no representation or warranties with respect to the accuracy, contrary interpretations of the subject matter herein, applicability, fitness or completeness of the contents. Therefore, if you wish to apply ideas contained on this website, you are taking full responsibility for your actions. The author and website owner specifically disclaim any liability that is incurred from the use or application of the contents sated here.

Please note that by continuing to read this site, you agree that you have read and understood this disclaimer and are continuing to read or utilize information from this site at your own responsibility and risk. Under no circumstances can you hold us responsible for any outcome or result from your having read or followed any of the expressions/suggestions/recommendations from this site.  We hope you expand your understanding and that many of the ideas and suggestions provided on this site help you. BUT we do not take on any implicit or explicit liability for anyone following any of those suggestions, ideas or advices. This is also applicable for any comments and discussions being carried out on this site.
 
For queries regarding any posted content, please feel free to contact the web administrator using contact form.
Terms & Conditions of site usage

©
2001- 2017 Copyrighted content, ALL RIGHTS RESERVED.


  • Shruti's Blog
  • About Shruti Bhat
  • QUALITY BLOG
  • Industry News
  • Free Ebook
  • Research Updates
    • Drug Research
    • Clinical Research
  • Contact